Different pathways such as myocarditis, pre-existing cardiovascular diseases, past cardiotoxic chemotherapy, uncommon myocardial metastases, old age, and systemic inflammatory conditions could contribute to arrhythmia in cancer patients treated with PD-1/PDL-1 inhibitors. The gene discussed is CD274; the disease is myocarditis.